The terms Ozempic, Wegovy, and Mounjaro have become some of the most-searched compound names in Australia. While these are brand names rather than research peptides themselves, understanding the active ingredients they contain — and their distinct research profiles — is essential for research literacy in the Australian peptide and metabolic science space.
This guide breaks down what each brand contains, how they differ, their TGA status in Australia, and what researchers need to know about the underlying compounds.
The Active Ingredients: What’s Inside Each Brand
Ozempic — Semaglutide
Ozempic is a brand name for semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist. It is a modified synthetic analogue of native GLP-1, engineered for extended half-life through:
- Fatty acid (C-18) side chain enabling albumin binding
- Amino acid substitutions protecting against DPP-4 enzymatic degradation
- Resulting in a half-life of approximately one week, allowing once-weekly administration
In research, semaglutide has been studied for its effects on:
- Glucose-dependent insulin secretion
- Glucagon suppression
- Gastric emptying delay
- Appetite regulation via central nervous system signalling
Ozempic is registered with the TGA in Australia for specific research-approved indications.
Explore semaglutide research: /peptides/semaglutide/
Wegovy — Also Semaglutide (Higher Dose)
Wegovy contains the same active ingredient as Ozempic — semaglutide — but is formulated for different research dose ranges and approved under a separate TGA registration for body mass management research applications.
The key difference between Ozempic and Wegovy is not the molecule but the:
- Dose range (Wegovy is studied at higher doses — up to 2.4mg weekly)
- Approved research indications (body mass-focused vs glycaemic-focused)
- Dosing titration schedule
Understanding that Ozempic and Wegovy contain the same research compound is critical for avoiding confusion in the literature.
Mounjaro — Tirzepatide
Mounjaro is a brand name for tirzepatide, a fundamentally different compound from semaglutide. Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors simultaneously.
This dual mechanism is what distinguishes tirzepatide research from semaglutide research:
- GIP receptor agonism may enhance insulin sensitivity and lipid metabolism
- Combined GIP/GLP-1 activation may produce additive effects on body mass and glycaemic markers
- The dual pathway represents a different research hypothesis from single-target GLP-1 agonism
Explore tirzepatide research: /peptides/tirzepatide/
Research Data Comparison
Semaglutide (Ozempic/Wegovy) Research
Semaglutide has one of the most extensive research databases in the incretin field:
- STEP programme (Wegovy/body mass): Multiple phase 3 trials showing consistent body mass reductions in the 15–17% range across diverse research cohorts
- SUSTAIN programme (Ozempic/glycaemic): Robust phase 3 data on glycaemic control markers
- SELECT trial: Large cardiovascular outcomes research study
- Oral semaglutide data: Research on non-injectable formulations
The depth of published semaglutide research makes it the most data-rich incretin compound available in the research literature.
Tirzepatide (Mounjaro) Research
Tirzepatide’s research database, while newer, is substantial:
- SURPASS programme: Phase 3 research comparing tirzepatide against semaglutide and other comparators for glycaemic markers
- SURMOUNT programme: Phase 3 research on body mass management outcomes
- SURPASS-2 (head-to-head vs semaglutide): Research showing tirzepatide produced greater reductions in HbA1c and body mass compared to semaglutide 1mg in the study cohort
- Growing real-world evidence research in multiple populations
Head-to-Head Research Summary
| Feature | Semaglutide (Ozempic/Wegovy) | Tirzepatide (Mounjaro) |
|---|---|---|
| Active compound | Semaglutide | Tirzepatide |
| Receptor targets | GLP-1 only | GIP + GLP-1 (dual) |
| Mechanism class | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| TGA registered (AU) | Yes — both Ozempic and Wegovy | Yes — Mounjaro |
| Regulatory schedule | S4 — Prescription Only | S4 — Prescription Only |
| Research depth | Very extensive | Extensive and growing |
| Head-to-head data | SURPASS-2 showed tirzepatide outperformed semaglutide 1mg | — |
| Half-life | ~1 week | ~5 days |
Australian TGA Status and Availability
Ozempic in Australia
Ozempic holds TGA registration and is classified as Schedule 4 (S4) — Prescription Only Medicine. It has been subject to significant supply constraints in Australia, which has impacted availability for both prescription use and research purposes. The TGA has issued multiple communications regarding Ozempic supply issues.
Wegovy in Australia
Wegovy has received TGA registration in Australia, also as an S4 compound. Availability and PBS listing status should be verified with current TGA resources, as this evolves.
Mounjaro in Australia
Mounjaro received TGA registration in Australia and is classified as S4 — Prescription Only. As a newer entrant to the Australian market, its availability and listing status may differ from semaglutide products.
Supply and Access Considerations
Australian researchers should be aware that:
- All three are registered S4 compounds requiring prescription through appropriate medical channels
- Supply constraints have been a significant factor in the Australian market
- The TGA has issued specific guidance around supply prioritisation
- Research use of these branded products differs from research-use-only peptide compounds
For researchers studying the underlying active ingredients (semaglutide and tirzepatide) rather than the branded products, separate regulatory pathways may apply. See: Are Peptides Legal in Australia?
The Bigger Picture: Beyond Brand Names
For Australian researchers, the key insight is that these brand names represent two distinct research compounds:
- Semaglutide — the GLP-1 receptor agonist (found in Ozempic and Wegovy)
- Tirzepatide — the dual GIP/GLP-1 receptor agonist (found in Mounjaro)
Understanding this distinction is fundamental to research literacy. When comparing research data, the meaningful comparison is between semaglutide and tirzepatide as compounds — not between brand names that may contain the same active ingredient at different doses.
For a deeper compound-level comparison, see: Semaglutide vs Tirzepatide: GLP-1 Research Compared
The next frontier in this research space is retatrutide — a triple GIP/GLP-1/glucagon agonist that represents the next evolution of incretin-based research. See: Retatrutide vs Tirzepatide
Frequently Asked Questions
What is the difference between Ozempic and Wegovy?
Ozempic and Wegovy contain the same active ingredient — semaglutide. The difference is in the approved dose range and research indications. Wegovy is studied and registered at higher doses for body mass management research, while Ozempic is studied at lower doses for glycaemic control research.
Is Mounjaro the same as Ozempic?
No. Mounjaro contains tirzepatide (a dual GIP/GLP-1 agonist), while Ozempic contains semaglutide (a GLP-1-only agonist). They are different research compounds with different mechanisms, despite belonging to the broader incretin family.
Which has better research data — semaglutide or tirzepatide?
Both have extensive phase 3 research data. Semaglutide has a larger overall published evidence base due to its longer time on the market. However, head-to-head research (SURPASS-2) showed tirzepatide producing greater reductions in glycaemic and body mass markers compared to semaglutide 1mg in the study population. Both have robust, peer-reviewed research.
Are Ozempic, Wegovy, and Mounjaro available in Australia?
All three have received TGA registration in Australia as Schedule 4 (S4) prescription compounds. However, availability has been affected by supply constraints. Researchers should check current TGA listings and supply status.
Where can I discuss GLP-1 research with other Australian researchers?
Join the Grey Highway Telegram community — an active community of Australian researchers discussing peptide and GLP-1 research, regulatory developments, and research methodology.
This guide is for educational and research literacy purposes only. It does not constitute medical or therapeutic advice. Brand names are used for identification purposes in a research context. Grey Highway promotes informed, responsible research literacy for Australian researchers.
Join the conversation: Grey Highway Telegram